

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE", B/H, SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 080.
Tel. No. :- 079-67778000, Fax. No.-079-67778082, email Id: info@lincolnpharma.com, CIN:L24230G19959PLC024288

UN-AUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED ON 30.06.2014

(Rs. In Lacs)

PART - I	PARTICULARS	CONSOLIDATED				STANDALONE			
		QUARTER ENDED 30.06.2014 (Un-Audited)	31.03.2014 (Audited)	30.06.2013 (Un-Audited)	31.03.2013 (Audited)	QUARTER ENDED 30.06.2014 (Un-Audited)	31.03.2014 (Audited)	30.06.2013 (Un-Audited)	31.03.2013 (Audited)
1	Income from operations	4894.95	6478.85	3795.38	20908.58	4637.06	6186.01	3742.60	20478.08
	(a) Net Sales/Income from operation (Net of excise duty)	216.02	196.85	205.29	618.15	196.90	129.22	180.62	511.05
	(b) Other operating income	4910.97	6675.70	4000.67	21526.73	4833.56	6315.23	3923.22	20989.13
	Total Income from operations (net)								
2	Expenses	1226.86	2081.01	911.70	5226.85	969.48	1472.20	589.69	4050.05
	(a) Cost of materials consumed	1272.87	2134.66	1395.66	9220.45	1702.20	3267.05	1813.81	10578.20
	(b) Purchases of stock-in-trade	277.89	38.22	-96.26	-314.09	218.60	61.84	-85.21	-209.31
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	432.46	471.76	488.06	1884.71	379.55	405.64	418.26	1618.77
	(d) Employee benefits expense	111.28	87.88	85.76	352.65	70.79	57.09	55.02	227.94
	(e) Depreciation and amortisation expense	983.68	814.13	797.57	3234.57	847.98	725.48	725.48	2931.26
	(f) Other expenses	4305.04	6227.60	3582.49	19615.14	4188.68	5982.29	3547.05	19196.81
	Total other expenses	6035.93	448.10	418.18	1971.59	645.28	322.94	376.17	1792.22
3	Profit/(Loss) from operations before other income/finance costs and exceptional items (1-2)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4	Other income	605.53	448.10	418.18	1911.59	645.28	322.94	376.17	1792.22
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	184.70	312.18	418.18	704.47	138.10	225.92	93.12	537.82
6	Finance costs	421.23	135.92	272.95	1207.12	507.18	97.02	283.05	1254.40
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8	Exceptional items	421.23	135.92	272.95	1207.12	507.18	97.02	283.05	1254.40
9	Profit/(Loss) from ordinary activities before tax (7+8)	421.23	135.92	272.95	1207.12	507.18	97.02	283.05	1254.40
10	Tax expense	117.44	58.58	-35.09	188.67	122.57	39.14	-66.99	111.64
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	303.79	77.34	308.04	1018.45	384.61	57.88	350.04	1142.76
12	Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit/(Loss) for the period (11-12)	303.79	77.34	308.04	1018.45	384.61	57.88	350.04	1142.76
14	Share of profit/(loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority interest*	-19.05	7.67	-16.06	-46.96	0.00	0.00	0.00	0.00
16	Net Profit/(Loss) after taxes, minority interest and shares of profit/(loss) of associates (13-14+15)*	322.84	69.67	324.10	1085.41	384.61	57.88	350.04	1142.76
17	Paid-up equity share capital of face value Rs.10/- each	1631.08	1631.08	1631.08	8252.84	1631.08	1631.08	1631.08	8281.66
18	Reserve excluding Revaluation Reserves as per balance sheet of previous 21c. Year	1.88	0.43	1.89	6.53	2.36	0.35	2.15	7.00
19	(a) Basic and diluted EPS before Extraordinary Items (16-18) and Prior Period Adjustment (Not Annualised)	1.98	0.43	1.89	6.53	2.36	0.35	2.15	7.00
19	(b) Basic and diluted EPS after Extraordinary Items (16-18) and Prior Period Adjustment (Not Annualised)	1.98	0.43	1.89	6.53	2.36	0.35	2.15	7.00
PART - II									
A. PARTICULARS OF SHAREHOLDING									
1	Public Shareholding:								
	- Number of Shares	10984449	10979649	10972268	10979649	10984449	10979649	10972268	10979649
	- Percentage of Shareholding	67.34	67.32	67.27	67.32	67.34	67.32	67.27	67.32
2	Promoters and Promoter group Shareholding:								
	a) Pledged/Encumbered	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-encumbered	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	- Number of Shares	5326351	5331151	5336532	5331151	5326351	5331151	5336532	5331151
	- Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shareholding (as a % of the total share capital of the Company)	32.66	32.68	32.73	32.68	32.66	32.68	32.73	32.68
B. INVESTOR COMPLAINTS									
	Pending at the beginning of the quarter	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	Received during the quarter	1	1	1	1	1	1	1	1
	Disposed of during the quarter	1	1	1	1	1	1	1	1
	Remaining unresolved at the end of the quarter	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL

NOTES:-
1. The above results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 14.08.2014
2. Consequent to the applicability of the Companies Act, 2013 (the Act) to Accounting periods commencing on or after April 1, 2014 the Company has computed the depreciation charge for the quarter with reference to the estimated useful lives of the Fixed Assets as prescribed in schedule II of the Act. Further, Rs.73,98,875/- the carrying value (net of residual value) of assets whose remaining useful life is Nil as on 1st April, 2014 has been recognised in the opening balance of retained earnings. Based on the past experience, residual value of computers is estimated @2-50% of the cost price instead of 5% of the cost price prescribed under schedule II to the Act.
3. Previous year figures are regrouped/reclassified to conform to the current year's presentation.
4. Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
5. Statutory Auditors has carried out limited review for the quarterly result for quarter ended 30.06.2014.
6. Consolidated results includes results of its two subsidiary Company
7. Company has opted to publish standalone Results for the year 2014-15

Place : Ahmedabad.
Date : 14.08.2014

for LINCOLN PHARMACEUTICALS LIMITED

(Mehendra Patel)
Managing Director

